Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

被引：5

作者：

Bernal, Teresa ^{[1
,2
]}

Fernandez Moreno, Ainhoa ^{[1
,2
]}

de LaIglesia, Almudena ^{[3
]}

Benavente, Celina ^{[4
]}

Garcia-Noblejas, Ana ^{[5
]}

Garcia Belmonte, Daniel ^{[6
]}

Riaza, Rosalia ^{[7
]}

Salamero, Olga ^{[8
]}

Angeles Foncillas, Maria ^{[9
]}

Roldan, Alicia ^{[10
]}

Noriega Concepcion, Victor ^{[11
]}

Llorente Gonzalez, Laura ^{[12
]}

Bergua Burgues, Juan Miguel ^{[13
,16
]}

Lorente de Una, Soraya ^{[14
]}

Rodriguez-Macias, Gabriela ^{[15
]}

de la Fuente Burguera, Adolfo

Garcia Perez, Maria Jose ^{[17
]}

Lopez-Lorenzo, Jose Luis ^{[18
]}

Martinez, Pilar ^{[19
]}

Alaez, Concepcion ^{[20
]}

Callejas, Marta ^{[21
]}

Martinez-Chamorro, Carmen ^{[22
]}

Rifon Roca, Jose ^{[23
]}

Amador Barciela, Lourdes ^{[24
]}

Mena Duran, Armando V. ^{[25
]}

Gomez Correcha, Karoll ^{[26
]}

Lavilla Rubira, Esperanza ^{[27
]}

Luz Amigo, Maria ^{[28
]}

Vall-llovera, Ferran ^{[29
]}

Garrido, Ana ^{[30
]}

Garcia-Fortes, Maria ^{[31
]}

de Miguel Llorente, Dunia ^{[32
]}

Aules Leonardo, Anastasia ^{[33
]}

Cervero, Carlos ^{[34
]}

Coll Jorda, Rosa ^{[35
]}

Perez-Encinas, Manuel M. ^{[36
]}

Polo Zarzuela, Marta ^{[4
]}

Figuera, Angela ^{[5
]}

Rad, Guillermo ^{[2
]}

Martinez-Cuadron, David ^{[37
]}

Montesinos, Pau

机构：

[1] Hosp Univ Cent Asturias, Oviedo, Spain

[2] Inst Invest Principado Asturias ISPA, Inst Oncol Principado Asturias IUOPA, Oviedo, Spain

[3] Hosp Puerta Hierro, Madrid, Spain

[4] Hosp Clin San Carlos, Madrid, Spain

[5] Hosp La Princesa, Madrid, Spain

[6] Hosp Univ Sanitas Zarzuela, Madrid, Spain

[7] Hosp Univ Severo Ochoa, Madrid, Spain

[8] Hosp Valle De Hebron, Barcelona, Spain

[9] Hosp Infanta Leonor, Madrid, Spain

[10] Univ Europea, Hosp Infanta Sofia San Sebastian de los Reyes, Dept Med, Madrid, Spain

[11] Complejo Hosp Univ A Coruna, La Coruna, Spain

[12] Hosp Univ HM Sanchinarro, Madrid, Spain

[13] Hosp San Pedro Alcantara, Caceres, Spain

[14] Hosp Vithas Xanit Int, Malaga, Spain

[15] Hosp Gregorio Maranon, Madrid, Spain

[16] MD Anderson Canc Ctr, Madrid, Spain

[17] Complejo Hosp Torre Cardenas, Almeria, Spain

[18] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[19] Hosp Univ Doce Octubre, Madrid, Spain

[20] Hosp Univ Moncloa, Madrid, Spain

[21] Hosp Univ Principe Asturias, Madrid, Spain

[22] Hosp Univ Quiron Pozuelo, Madrid, Spain

[23] Clin Univ Navarra, Pamplona, Spain

[24] Complejo Hosp Pontevedra, Pontevedra, Spain

[25] Consorcio Hosp Gen Univ Valencia, Valencia, Spain

[26] Hosp Juan Ramon Jimenez, Huelva, Spain

[27] Hosp Lucus Augusti, Lugo, Spain

[28] Hosp Gen Univ Morales Messeguer, Murcia, Spain

[29] Hosp Mutua Tarrasa, Barcelona, Spain

[30] Hosp Santa Creu i Sant Pau, Barcelona, Spain

[31] Hosp Univ Virgen Victoria, Malaga, Spain

[32] Hosp Univ Guadalajara, Guadalajara, Spain

[33] Hosp Miguel Servet, Zaragoza, Spain

[34] Hosp Virgen Luz, Cuenca, Spain

[35] Hosp Univ Dr Josep Trueta, ICO Girona, Girona, Spain

[36] Hosp Univ Santiago Compostela, Santiago, Spain

[37] Hosp Univ & Politecn La Fe, Valencia, Spain

来源：

CANCER MEDICINE | 2023年 / 12卷 / 14期

关键词：

acute myeloid leukemia; clinical observations; intensive chemotherapy; real-world; OLDER PATIENTS; SECONDARY; RECOMMENDATIONS; DIAGNOSIS; FEATURES; AML;

D O I：

10.1002/cam4.6120

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real-life patients. Methods: Retrospective analysis of AML patients treated with CPX-351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry. Results: Median age of 79 patients treated with CPX-351 was 67 years old (interquartile range 62-71), 53 were MRC-AML. The complete remission (CR) rate or CR without recovery (CRi) after 1 or 2 cycles of CPX-351 was 52%, 60-days mortality 18%, measurable residual disease <0.1% in 54% (12 out of 22) of them. Stem cell transplant (SCT) was performed in 27 patients (34%), median OS was 10.3 months, and 3-year relapse incidence was 50%. Using PSM, we obtained two comparable cohorts treated with CPX-351 (n = 52) or IC (n = 99), without significant differences in CR/CRi (60% vs. 54%) and median OS (10.3 months vs. 9.1 months), although more patients were bridged to SCT in the CPX-351 group (35% vs. 12%). The results were confirmed when only 3 + 7 patients were included in the historical cohort. In multivariable analyses, SCT was associated with better OS (HR 0.33 95% CI: 0.18-0.59), p < 0.001. Conclusion: Larger post-authorization studies may provide evidence of the clinical benefits of CPX-351 for AML in the real-life setting.

引用

页码：14892 / 14901

页数：10

共 17 条

[1] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
Cheson, BD
Bennett, JM
Kopecky, KJ
Büchner, T
Willman, CL
Estey, EH
Schiffer, CA
Döhner, H
Tallman, MS
Lister, TA
LoCocco, F
Willemze, R
Biondi, A
Hiddemann, W
Larson, RA
Löwenberg, B
Sanz, MA
Head, DR
Ohno, R
Bloomfield, CD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
[2] Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
Chiche, Edmond
Rahme, Ramy
Bertoli, Sarah
Dumas, Pierre-Yves
Micol, Jean-Baptiste
Hicheri, Yosr
Pasquier, Florence
Peterlin, Pierre
Chevallier, Patrice
Thomas, Xavier
Loschi, Michael
Genthon, Alexis
Legrand, Ollivier
Mohty, Mohamad
Raffoux, Emmanuel
Auberger, Patrick
Caulier, Alexis
Joris, Magalie
Bonmati, Caroline
Roth-Guepin, Gabrielle
Lejeune, Caroline
Pigneux, Arnaud
Vey, Norbert
Recher, Christian
Ades, Lionel
Cluzeau, Thomas
[J]. BLOOD ADVANCES, 2021, 5 (01) : 176 - 184
[3] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Doehner, Hartmut
Estey, Elihu
Grimwade, David
Amadori, Sergio
Appelbaum, Frederick R.
Buechner, Thomas
Dombret, Herve
Ebert, Benjamin L.
Fenaux, Pierre
Larson, Richard A.
Levine, Ross L.
Lo-Coco, Francesco
Naoe, Tomoki
Niederwieser, Dietger
Ossenkoppele, Gert J.
Sanz, Miguel
Sierra, Jorge
Tallman, Martin S.
Tien, Hwei-Fang
Wei, Andrew H.
Lowenberg, Bob
Bloomfield, Clara D.
[J]. BLOOD, 2017, 129 (04) : 424 - 447
[4] CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
Guolo, Fabio
Fianchi, Luana
Minetto, Paola
Clavio, Marino
Gottardi, Michele
Galimberti, Sara
Rizzuto, Giuliana
Rondoni, Michela
Bertani, Giambattista
Dargenio, Michela
Bilio, Atto
Scappini, Barbara
Zappasodi, Patrizia
Scattolin, Anna Maria
Grimaldi, Francesco
Pietrantuono, Giuseppe
Musto, Pellegrino
Cerrano, Marco
D'Ardia, Stefano
Audisio, Ernesta
Cignetti, Alessandro
Pasciolla, Crescenza
Pavesi, Francesca
Candoni, Anna
Gurreri, Carmela
Morselli, Monica
Alati, Caterina
Fracchiolla, Nicola
Rossi, Giovanni
Caizzi, Manuela
Carnevale-Schianca, Fabrizio
Tafuri, Agostino
Rossi, Giuseppe
Ferrara, Felicetto
Pagano, Livio
Lemoli, Roberto Massimo
[J]. BLOOD CANCER JOURNAL, 2020, 10 (10)
[5] Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
Hulegardh, Erik
Nilsson, Christer
Lazarevic, Vladimir
Garelius, Hege
Antunovic, Petar
Rangert Derolf, Asa
Mollgard, Lars
Uggla, Bertil
Wennstrom, Lovisa
Wahlin, Anders
Hoglund, Martin
Juliusson, Gunnar
Stockelberg, Dick
Lehmann, Soren
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (03) : 208 - 214
[6] CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Lancet, Jeffrey E.
Uy, Geoffrey L.
Cortes, Jorge E.
Newell, Laura F.
Lin, Tara L.
Ritchie, Ellen K.
Stuart, Robert K.
Strickland, Stephen A.
Hogge, Donna
Solomon, Scott R.
Stone, Richard M.
Bixby, Dale L.
Kolitz, Jonathan E.
Schiller, Gary J.
Wieduwilt, Matthew J.
Ryan, Daniel H.
Hoering, Antje
Banerjee, Kamalika
Chiarella, Michael
Louie, Arthur C.
Medeiros, Bruno C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2684 - +
[7] Modeling survival data: Extending the Cox model.
Li, JCA
[J]. SOCIOLOGICAL METHODS & RESEARCH, 2003, 32 (01) : 117 - 120
[8] Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Martinez-Cuadron, D.
Montesinos, P.
Vellenga, E.
Bernal, T.
Salamero, O.
Holowiecka, A.
Brunet, S.
Gil, C.
Benavente, C.
Ribera, J. M.
Perez-Encinas, M.
De la Serna, J.
Esteve, J.
Rubio, V.
Gonzalez-Campos, J.
Escoda, L.
Amutio, M. E.
Arnan, M.
Arias, J.
Negri, S.
Lowenberg, B.
Sanz, M. A.
[J]. LEUKEMIA, 2018, 32 (01) : 21 - 29
[9] Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study
Ostgard, Lene Sofie Granfeldt
Medeiros, Bruno C.
Sengelov, Henrik
Norgaard, Mette
Andersen, Mette Klarskov
Dufva, Inge Hogh
Friis, Lone Smidstrup
Kjeldsen, Eigil
Marcher, Claus Werenberg
Preiss, Birgitte
Severinsen, Marianne
Norgaard, Jan Maxwell
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) : 3641 - +
[10] Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia
Pagano, L
Pulsoni, A
Tosti, ME
Avvisati, G
Mele, L
Mele, A
Martino, B
Visani, G
Cerri, R
Di Bona, E
Invernizzi, R
Nosari, A
Clavio, M
Allione, B
Coser, P
Candoni, A
Levis, A
Camera, A
Melillo, L
Leone, G
Mandelli, F
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) : 109 - 117

← 1 2 →